New strategies in ewing sarcoma: Lost in translation?

Fernanda I. Arnaldez, Lee J. Helman

Research output: Contribution to journalArticle

Abstract

Ewing sarcoma is the second most common pediatric malignant bone tumor. Aggressive multimodality therapy has led to an improvement in outcomes, particularly in patients with localized disease. However, therapy-related toxicities are not trivial, and the prognosis for patients with relapsed and/or metastatic disease continues to be poor. In this article, we outline some of the promising therapies that have the potential to change the Ewing sarcoma therapeutic paradigm in the not-too-distant future: insulin-like growth factor receptor inhibitors, targeting of the fusion protein, epigenetic manipulation, PARP inhibitors, and immunotherapy.

Original languageEnglish (US)
Pages (from-to)3050-3056
Number of pages7
JournalClinical Cancer Research
Volume20
Issue number12
DOIs
StatePublished - Jun 15 2014

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'New strategies in ewing sarcoma: Lost in translation?'. Together they form a unique fingerprint.

  • Cite this